Literature DB >> 2291662

Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections.

C R Marchbanks1, D J Mikolich, K H Mayer, S H Zinner, M N Dudley.   

Abstract

The pharmacokinetics of oral fluoroquinolone antibiotics in normal volunteers have been studied extensively; however, limited patient data exist. Enoxacin steady-state pharmacokinetics and bioavailability were determined following repeated 400-mg intravenous (i.v.) and oral dosing by using compartmental and noncompartmental methods in 10 elderly (mean age, 73.8 years) men with complicated urinary tract infections. Average peak enoxacin concentrations following i.v. and oral dosing were 8.15 and 5.45 mg/liter, respectively. Mean values for major pharmacokinetic parameters (noncompartmental) were similar following i.v. and oral administration, respectively: area under the concentration-time curve from 0 to 12 h, 47.6 and 41.0 mg.h/liter; volume of distribution or volume of distribution/bioavailability, 1.61 and 1.99 liters/kg; total body clearance or total body clearance/bioavailability, 2.58 and 3.01 ml/min per kg; and half-life, 8.2 and 9.1 h. Parameters from analysis of enoxacin plasma concentration data by using a two-compartment pharmacokinetic model also revealed marked similarities between the two administration routes. Enoxacin was highly bioavailable (mean, 86.97%) following oral administration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2291662      PMCID: PMC171973          DOI: 10.1128/AAC.34.10.1966

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.

Authors:  K G Naber; F Sörgel; F Gutzler; B Bartosik-Wich
Journal:  Infection       Date:  1985 Sep-Oct       Impact factor: 3.553

3.  Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients.

Authors:  A P Ball; C Fox; M E Ball; I R Brown; J V Willis
Journal:  J Antimicrob Chemother       Date:  1986-05       Impact factor: 5.790

4.  Pharmacokinetics of ciprofloxacin in elderly subjects.

Authors:  M LeBel; G Barbeau; M G Bergeron; D Roy; F Vallée
Journal:  Pharmacotherapy       Date:  1986 Mar-Apr       Impact factor: 4.705

Review 5.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

6.  Noncompartmental determination of the steady-state volume of distribution during multiple dosing.

Authors:  I L Smith; J J Schentag
Journal:  J Pharm Sci       Date:  1984-02       Impact factor: 3.534

7.  The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers.

Authors:  R Wolf; R Eberl; A Dunky; N Mertz; T Chang; J R Goulet; J Latts
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

Review 8.  Drug therapy: drug disposition in old age.

Authors:  D J Greenblatt; E M Sellers; R I Shader
Journal:  N Engl J Med       Date:  1982-05-06       Impact factor: 91.245

9.  The activity of enoxacin against clinical bacterial isolates in comparison with that of five other agents, and factors affecting that activity.

Authors:  D S Reeves; M J Bywater; H A Holt
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

Review 10.  Enoxacin absorption and elimination characteristics.

Authors:  R D Toothaker
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

View more
  2 in total

1.  A randomised controlled trial of ofloxacin 200 mg 4 times daily or twice daily vs ciprofloxacin 500 mg twice daily in elderly nursing home patients with complicated UTI.

Authors:  J D McCue; P Gaziano; D Orders
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 2.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.